Chronic Elevation of Systemic Glucagon-Like Peptide-1 Following Surgical Weight Loss: Association with Nausea and Vomiting and Effects on Adipokines

Obesity Surgery

Volumn 25, Issue 2, 2015, Pages 386-391

  Al Rasheid, Noora ^a   Gray, Rosaire ^b   Sufi, Pratik ^b   Marina Gonzalez, Nephtali ^a   Al Sayrafi, Mohammed ^c   Atherton, Elizabeth ^b   Mohamed Ali, Vidya ^a,c  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b WHITTINGTON HOSPITAL   (United Kingdom)

^c Anti Doping Lab Qatar   (Qatar)

Author keywords

Adipokines; GLP 1; Nausea

Indexed keywords

GLUCAGON LIKE PEPTIDE 1; INSULIN; ADIPOCYTOKINE; GLUCOSE BLOOD LEVEL; LEPTIN;

ABDOMINAL SUBCUTANEOUS FAT; ADIPOSE TISSUE; ADULT; ANTHROPOMETRY; ARTICLE; CLINICAL ARTICLE; DIET RESTRICTION; FEMALE; GASTROINTESTINAL TRANSIT; GLUCOSE BLOOD LEVEL; HUMAN; IN VITRO STUDY; MALE; NAUSEA AND VOMITING; PRIORITY JOURNAL; STOMACH BYPASS; SUBCUTANEOUS FAT; WEIGHT REDUCTION; ADVERSE EFFECTS; BLOOD; CASE CONTROL STUDY; GASTRIC BYPASS SURGERY; INSULIN RESISTANCE; METABOLISM; MIDDLE AGED; NAUSEA; OBESITY, MORBID; PHYSIOLOGY; POSTOPERATIVE NAUSEA AND VOMITING; POSTPRANDIAL STATE; VOMITING;

ADIPOKINES; ADULT; BLOOD GLUCOSE; CASE-CONTROL STUDIES; FEMALE; GASTRIC BYPASS; GLUCAGON-LIKE PEPTIDE 1; HUMANS; INSULIN; INSULIN RESISTANCE; LEPTIN; MIDDLE AGED; NAUSEA; OBESITY, MORBID; POSTOPERATIVE NAUSEA AND VOMITING; POSTPRANDIAL PERIOD; VOMITING; WEIGHT LOSS;

EID: 84925491910     PISSN: 09608923     EISSN: 17080428     Source Type: Journal    
DOI: 10.1007/s11695-014-1507-4     Document Type: Article

References (19)

1. Sjöström L, Narbro K, Sjöström CD, Karason K, Larsson B, Wedel H, et al. Effects of bariatric surgery on mortality in Swedish obese subjects. New Engl J Med. 2007;357:741–52.
2. Teixeira FV, Novaretti TM, Pilon B, Pereira PG, Breda MF. Mirtazapine (Remeron) as treatment for non-mechanical vomiting after gastric bypass. Obes Surg. 2005;15:707–9.
3. Jacobs M, Bisland W, Gomez E, Plasenica G, Mederos R, Celaya C, et al. Laparoscopic sleeve gastrectomy: a retrospective review of 1- and 2-year results. Surg Endosc. 2010;24:781–5.
4. Meier JJ, Nauck MA. Glucagon-like peptide 1 (GLP-1) in biology and pathology. Diabetes Metab Res Rev. 2005;21:91–117.
5. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care. 2005;28:1092–100.
6. Kanoski SE, Rupprecht LE, Fortin SM, De Jonghe BC, Hayes MR. The role of nausea in food intake and body weight suppression by peripheral GLP-1 receptor agonists, exendin-4 and liraglutide. Neuropharmacology. 2012;62:1916–27.
7. Dar MS, Champman WH, Pender JR, Drake AJ, O’Brien K, Tanenberg RJ, et al. GLP-1 response to mixed meal: what happens 10 years after Roux-en-y gastric bypass (RYGB)? Obs Surg. 2012;7:1077–83.
8. Naslund E, Knal JG. Impact of gastric bypass surgery on gut hormones and glucose homeostasis in type 2 diabetes. Diabetes. 2006;55(suppl2):S92–7.
9. Kuo SH, Yang YH, Wang RH, Chan TF, Chou FH. Relationships between leptin, HCG, cortisol, and psychosocial stress and nausea and vomiting throughout pregnancy. Biol Res Nurs. 2010;12:20–7.
10. Aka N, Atalay S, Sayharman S, Kiliç D, Köse G, Küçüközkan T. Leptin and leptin receptor levels in pregnant women with hyperemesis gravidarum. Aust N Z J Obstet Gynaecol. 2006;46:274–7.
11. Ravussin E, Smith SR, Mitchell JA, Shringarpure R, Shan K, Maier H, et al. Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy. Obesity (Silver Spring). 2009;17(9):1736–43.
12. Abell TL, Minocha A. Gastrointestinal complications of bariatric surgery: diagnosis and therapy. A J Med Sci. 2006;331(4):214–8.
13. Romero F, Nicolau J, Flores L, Casamitjana R, Ibarzadal A, Lacy A, et al. Comparable early changes in gastrointestinal hormones after sleeve gastrectomy and Rou-en-Y gastric bypass surgery for morbidly obese type 2 diabetes subjects. Surg Endosc. 2012;26(8):2231–9.
14. Bala M, Martin J, Kopp A, Hanses F, Buechler C, Schaffler A. In vivo suppression of visfatin by oral glucose uptake: evidence for a novel incretin-like effect by glucagon-like peptide-1 (GLP-1). J Clin Endocrinol Metab. 2011;96:2493–501.
15. Kim Chung LE T, Hosaka T, Yoshida M, Harada N, Sakaue H, Sakai T, et al. Exendin-4, a GLP-1 receptor agonist, directly induces adiponectin expression through protein kinase A pathway and prevents inflammatory adipokine expression. Biochem Biophys Res Commun. 2009;390:613–8.
16. Daousi C, Pinkney JH, Cleator J, Wilding JP, Ranganath LR. Acute peripheral administration of synthetic human GLP-1 (7–36 amide) decreases circulating IL-6 in obese patients with type 2 diabetes mellitus: a potential role for GLP-1 in modulation of the diabetic pro-inflammatory state? Regul Pept. 2013;183C:54–61.
17. Anini Y, Brubaker PL. Role of leptin in the regulation of glucagon-like peptide-1 secretion. Diabetes. 2003;52:252–9.
18. le Roux CW, Welbourn R, Werling M, Osborne A, Kokkinos A, Laurenius A, et al. Gut hormones as mediators of appetite and weight loss after Roux-en-Y gastric bypass. Ann Surg. 2007;246:780–5.
19. Rubino F, Gagner M, Gentileschi P, Kini S, Fukuyama S, Feng J, et al. The early effect of the Roux-en-Y gastric bypass on hormones involved in body weight regulation and glucose metabolism. Ann Surg. 2004;240:236–42.